Cediranib – 5 mg

Brand:
Cayman
CAS:
288383-20-0
Storage:
-20
UN-No:
Non-Hazardous - 2811 / 6.1

Receptors for VEGF have central roles in vasculogenesis and angiogenesis and thus serve as targets for cancer therapy.{18368,20203} Cediranib is a potent inhibitor of VEGF receptor tyrosine kinases, including VEGFR1, 2, and 3 (IC50s = 5, 1, and 3 nM, respectively).{24157} It also potently inhibits a variety of other receptor and non-receptor tyrosine kinases, including several in the platelet-derived growth factor, fibroblast growth factor, and endothelial growth factor receptor families.{24157,24156} Cediranib blocks tubule formation by human umbilical vein endothelial cells in vitro and prevents angiogenesis as well as xenograft tumor growth in vivo.{24157} Because of these effects, cediranib has potential use in a range of cancers.{19939,24159,24155}  

 

Available on backorder

SKU: 11495 - 5 mg Category:

Description

A potent inhibitor of VEGFR1, 2, and 3 (IC50s = 5, 1, and 3 nM, respectively); also potently inhibits a variety of other receptor and non-receptor tyrosine kinases; blocks tubule formation by HUVECs in vitro and prevents angiogenesis as well as xenograft tumor growth in vivo


Formal name: 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-quinazoline

Synonyms:  AZD 2171|ZD 2171

Molecular weight: 450.5

CAS: 288383-20-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|EGFR/ErbB/HER Family||Product Type|Biochemicals|Kinase Inhibitors|FGFR Family||Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling